CRYBA2

Across TCGA pan-cancer cohorts, CRYBA2 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated CRYBA2 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CRYBA2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CRYBA2 expression acts as an unfavorable survival marker, although some lineages such as PAAD and CESC show a favorable association.

KIRC, MESO, and THYM are the cancer types where CRYBA2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Tertile	All	0.538	0.657	<.001	110	view →
MESO	OS	Median	All	0.251	0.508	<.001	73	view →
THYM	DFS	Tertile	All	0.522	0.934	<.001	61	view →
BLCA	DFS	Quartile	IV	0.280	0.519	<.001	57	view →
PAAD	DFS	Median	All	0.380	0.177	<.001	50	view →
ESCA	OS	Median	All	0.388	0.611	.001	37	view →
SKCM	OS	Median	II,III,IV	0.748	0.925	<.001	30	view →
DLBC	DFS	Quartile	All	0.263	0.832	.002	27	view →
COAD	DFS	Tertile	IV	0.345	0.676	.002	22	view →
UCEC	OS	Tertile	IV	0.358	0.706	.013	20	view →
LIHC	OS	Tertile	III,IV	0.187	0.596	.001	18	view →
ACC	OS	Median	III,IV	0.318	0.878	.001	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

CRYBA2–KIRC (OS)

Open the KIRC breakdown →